Novanta (NASDAQ:NOVT) CFO Robert Buckley Sells 9,957 Shares of Stock

Novanta Inc. (NASDAQ:NOVT) CFO Robert Buckley sold 9,957 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $116.77, for a total value of $1,162,678.89. Following the transaction, the chief financial officer owned 96,616 shares of the company’s stock, valued at approximately $11,281,850.32. The trade was a 9.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Buckley also recently made the following trade(s):

• On Friday, February 20th, Robert Buckley sold 1,423 shares of Novanta stock. The stock was sold at an average price of $140.88, for a total value of $200,472.24.
• On Wednesday, January 21st, Robert Buckley sold 1,423 shares of Novanta stock. The shares were sold at an average price of $140.14, for a total value of $199,419.22.

Novanta Stock Performance

Shares of NOVT opened at $119.33 on Thursday. Novanta Inc. has a 12-month low of $98.27 and a 12-month high of $149.95. The company has a current ratio of 3.69, a quick ratio of 2.80 and a debt-to-equity ratio of 0.16. The company has a market cap of $4.26 billion, a PE ratio of 81.73 and a beta of 1.61. The stock has a 50-day moving average price of $135.24 and a 200-day moving average price of $121.21.

Novanta (NASDAQ:NOVT) last announced its earnings results on Monday, February 23rd. The technology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novanta had a net margin of 5.49% and a return on equity of 13.12%. The business had revenue of $258.35 million for the quarter, compared to the consensus estimate of $260.72 million. During the same period last year, the firm posted $0.76 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. As a group, equities analysts forecast that Novanta Inc. will post 3.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Robert W. Baird set a $150.00 target price on shares of Novanta in a research report on Wednesday, February 25th. Zacks Research upgraded Novanta from a “strong sell” rating to a “hold” rating in a research report on Friday, January 16th. Finally, Weiss Ratings raised Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $150.00.

Institutional Investors Weigh In On Novanta

Hedge funds have recently made changes to their positions in the business. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Novanta during the 3rd quarter valued at $36,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Novanta in the third quarter worth $40,000. Danske Bank A S purchased a new stake in Novanta during the third quarter valued at about $40,000. Allworth Financial LP grew its stake in shares of Novanta by 978.4% during the fourth quarter. Allworth Financial LP now owns 399 shares of the technology company’s stock valued at $47,000 after buying an additional 362 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Novanta by 120.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock valued at $51,000 after buying an additional 233 shares during the last quarter. 98.35% of the stock is currently owned by institutional investors.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.